The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have...

Full description

Bibliographic Details
Main Authors: Gagandeep Brar, Manish A. Shah
Format: Article
Language:English
Published: SAGE Publishing 2019-08-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284819869767
id doaj-436b0d7e0dbd4b6f97e9b2157047c56b
record_format Article
spelling doaj-436b0d7e0dbd4b6f97e9b2157047c56b2020-11-25T03:49:55ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482019-08-011210.1177/1756284819869767The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinomaGagandeep BrarManish A. ShahGastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.https://doi.org/10.1177/1756284819869767
collection DOAJ
language English
format Article
sources DOAJ
author Gagandeep Brar
Manish A. Shah
spellingShingle Gagandeep Brar
Manish A. Shah
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
Therapeutic Advances in Gastroenterology
author_facet Gagandeep Brar
Manish A. Shah
author_sort Gagandeep Brar
title The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_short The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_full The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_fullStr The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_full_unstemmed The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_sort role of pembrolizumab in the treatment of pd-l1 expressing gastric and gastroesophageal junction adenocarcinoma
publisher SAGE Publishing
series Therapeutic Advances in Gastroenterology
issn 1756-2848
publishDate 2019-08-01
description Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.
url https://doi.org/10.1177/1756284819869767
work_keys_str_mv AT gagandeepbrar theroleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT manishashah theroleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT gagandeepbrar roleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT manishashah roleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
_version_ 1724493288231141376

Similar Items